2251-62-9 Usage
Uses
Used in Pharmaceutical Industry:
4-Chloro-6-fluorocinnoline is used as a building block for the synthesis of biologically active molecules, playing a crucial role in the development of new pharmaceutical compounds. Its unique structure allows for the creation of drugs with specific therapeutic properties, targeting a range of medical conditions.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 4-Chloro-6-fluorocinnoline serves as a key component in the synthesis of active ingredients for pesticides, herbicides, and other crop protection agents. Its incorporation enhances the effectiveness of these products, contributing to improved agricultural yields and pest management.
Used as a Reagent in Organic Chemistry:
4-Chloro-6-fluorocinnoline is also utilized as a reagent in various organic chemistry reactions. Its presence can facilitate or catalyze specific chemical transformations, making it an indispensable tool for researchers and chemists in the field of organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 2251-62-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,5 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 2251-62:
(6*2)+(5*2)+(4*5)+(3*1)+(2*6)+(1*2)=59
59 % 10 = 9
So 2251-62-9 is a valid CAS Registry Number.
2251-62-9Relevant articles and documents
5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS
-
Page/Page column 50, (2012/05/20)
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention aLso enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo- dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
